var data={"title":"Oral isotretinoin therapy for acne vulgaris","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Oral isotretinoin therapy for acne vulgaris</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributors\" class=\"contributor contributor_credentials\">Cindy Owen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributors\" class=\"contributor contributor_credentials\">Mark V Dahl, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 27, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (13-cis retinoic acid) is effective for the treatment of severe recalcitrant nodular acne. However, isotretinoin is associated with multiple adverse effects and is teratogenic. Thus, it must be used with appropriate caution in selected patients.</p><p>This topic will discuss clinical use of oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> and related safety concerns. The pathogenesis, clinical manifestations, diagnosis, and conventional treatment of acne vulgaris are discussed separately. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;</a> and <a href=\"topic.htm?path=hormonal-therapy-for-women-with-acne-vulgaris\" class=\"medical medical_review\">&quot;Hormonal therapy for women with acne vulgaris&quot;</a> and <a href=\"topic.htm?path=treatment-of-acne-vulgaris\" class=\"medical medical_review\">&quot;Treatment of acne vulgaris&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> counteracts the pathogenic factors that contribute to the development of acne vulgaris [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Therapy leads to shrinkage of sebaceous glands and a marked attenuation of sebum secretion. The decrease in sebum results in the inhibition of the sebum-dependent bacterium <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em>, which is a key promoter of inflammation in acne vulgaris. Oral isotretinoin also inhibits comedogenesis by fostering keratinocyte differentiation and by normalizing desquamation.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL USE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is effective for the treatment of acne vulgaris [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/3-10\" class=\"abstract_t\">3-10</a>]. The first study to show the benefit of oral isotretinoin was a case series of 14 patients with treatment-resistant severe acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/3\" class=\"abstract_t\">3</a>]. After four months of treatment, 13 out of 14 patients experienced complete clearance of their disease.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, the Food and Drug Administration (FDA) approved usage of oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> only for severe, recalcitrant, nodular acne. &quot;Severe, recalcitrant, nodular acne&quot; is defined as acne with many (greater than 5 mm) inflammatory nodules that is unresponsive to conventional therapy, including systemic antibiotics.</p><p>Clinicians also prescribe oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> for selected patients without severe nodular recalcitrant acne. Patients for whom isotretinoin may be considered include those with the following (see <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment-resistant acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/11,12\" class=\"abstract_t\">11,12</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scarring acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/12\" class=\"abstract_t\">12</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acne causing significant psychologic distress [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/12\" class=\"abstract_t\">12</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acne fulminans [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/13,14\" class=\"abstract_t\">13,14</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibiotic-induced gram-negative folliculitis in patients with acne vulgaris [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/15,16\" class=\"abstract_t\">15,16</a>]</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment is initiated at a dose of 0.5 <span class=\"nowrap\">mg/kg/day</span> for the first month of therapy, and is subsequently increased to 1 <span class=\"nowrap\">mg/kg/day</span>. Dosing can be once or twice daily. The total treatment goal is 120 to 150 <span class=\"nowrap\">mg/kg,</span> and is typically reached over four to six months (usual duration of treatment 20 weeks) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/12\" class=\"abstract_t\">12</a>]. The drug is discontinued without tapering. There is some evidence that lower doses may also be effective [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/17\" class=\"abstract_t\">17</a>]. </p><p>Absorption of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is improved when taken with food (especially high-fat meals); thus, administration during meals is recommended. A newer formulation of isotretinoin (isotretinoin with Lidose technology) demonstrates increased bioavailability in the fasting state [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/18\" class=\"abstract_t\">18</a>]. This formulation is dosed twice daily and can be given without regard to meals.</p><p>Other acne medications are typically discontinued during <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy. Isotretinoin causes temporary xerosis, cutaneous atrophy, and skin fragility [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>], and topical acne medications may be poorly tolerated. Isotretinoin should not be given with <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> antibiotics due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri) associated with both of these drugs.</p><p>Acne may initially worsen with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy; initiating therapy at 0.5 <span class=\"nowrap\">mg/kg/day</span> during the first month may decrease this risk. The early flare typically resolves with further treatment [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>]. More severe flares may occur in patients presenting with severe inflammatory acne (eg, acne conglobata, acne fulminans). In some of these cases, the inflammatory nodules may ulcerate or form exuberant granulation tissue. If this happens, isotretinoin is temporarily stopped. Systemic glucocorticoids (0.5 to 1 <span class=\"nowrap\">mg/kg/day)</span> are sometimes given before isotretinoin therapy or concurrently for the first two to four weeks of treatment in an attempt to prevent severe flares. Rarely, isotretinoin may induce acne fulminans [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/19,20\" class=\"abstract_t\">19,20</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris#H12\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;, section on 'Acne variants'</a>.)</p><p><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> is associated with a number of adverse effects that can be severe and limit its use. Isotretinoin should only be prescribed by clinicians who are completely familiar with the medication. In the US, the FDA has imposed restrictions on who may prescribe and distribute isotretinoin. (See <a href=\"#H7\" class=\"local\">'Isotretinoin safety'</a> below.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">RESPONSE TO THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is the only acne medication that can permanently alter the natural course of the disorder. The majority of patients experience long-term improvement in acne severity after one course of treatment [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/21\" class=\"abstract_t\">21</a>]. Continued improvement may occur for several months after cessation of therapy; at least five months should elapse before considering retreatment with isotretinoin. </p><p>The vast majority of relapses (96 percent) occur within the first three years of stopping therapy; the highest relapse rates occur in patients with predominantly truncal acne or in those receiving a total cumulative dose of less than 120 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/21\" class=\"abstract_t\">21</a>]. Reported relapse rates for patients treated with 120 to 150 <span class=\"nowrap\">mg/kg</span> of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> range between 20 and 60 percent [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/22\" class=\"abstract_t\">22</a>]. In one study of 88 patients, 82 percent of patients who received cumulative doses &lt;120 <span class=\"nowrap\">mg/kg</span> relapsed, compared with only 20 percent of patients given &gt;120 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/21\" class=\"abstract_t\">21</a>]. Patients who receive isotretinoin as young teenagers (under age 16) may also have an increased risk for relapse [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/23\" class=\"abstract_t\">23</a>].</p><p>Despite the high response rate after a single course of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, only a minority of patients are truly cured. In one series, 39 percent were cured but 61 percent still required the use of topical therapy (16.9 percent), topical therapy plus an oral antibiotic (25.3 percent), or another course of isotretinoin (18.8 percent) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/24\" class=\"abstract_t\">24</a>]. Following isotretinoin treatment, acne is more likely to be responsive to conventional therapies [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/25\" class=\"abstract_t\">25</a>]. Response rates after a second course of isotretinoin are similar to those following the initial course of treatment [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H29706373\"><span class=\"h2\">Low dose isotretinoin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Doses of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> lower than 0.5 <span class=\"nowrap\">mg/kg/day</span> may be effective for the treatment of some patients with acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/17,26\" class=\"abstract_t\">17,26</a>]. In a 24-week single-blind randomized trial, 60 patients with moderate acne were treated with one of three regimens of isotretinoin: 0.5 to 0.7 <span class=\"nowrap\">mg/kg/day</span> (higher dose regimen), 0.25 to 0.4 <span class=\"nowrap\">mg/kg/day</span> (lower dose regimen), or 0.5 to 0.7 <span class=\"nowrap\">mg/kg</span> daily for one week every four weeks (intermittent regimen) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/26\" class=\"abstract_t\">26</a>]. All three treatment courses resulted in clinically significant improvement. The lower dose and higher dose regimens were similarly effective and had equivalent rates of relapse after one year; however, more adverse effects were reported in the higher dose group during treatment. A lesser degree of improvement and a lower duration of effect were detected in the patients who received intermittent therapy.</p><p>The results of this trial suggest that treatment with less than 0.5 <span class=\"nowrap\">mg/kg/day</span> of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is as effective as a slightly higher dose regimen in patients with moderate acne and is associated with fewer adverse effects. Of note, the study excluded individuals with severe acne, a group of patients for which isotretinoin therapy is frequently indicated.</p><p class=\"headingAnchor\" id=\"H82308305\"><span class=\"h2\">High-dose isotretinoin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is some evidence that high cumulative doses of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> may reduce the risk of relapse in patients with severe acne vulgaris [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/22,27\" class=\"abstract_t\">22,27</a>]. A prospective observational study of 180 patients with severe nodular acne resistant to other therapies found significantly lower rates of relapse one year after treatment cessation among patients who received a cumulative dose of isotretinoin &ge;220 <span class=\"nowrap\">mg/kg</span> than those who received lower cumulative doses; 26.9 percent [95% CI 18.3-37.8 percent] versus 47.4 percent [95% CI 32.3-63.0 percent] relapsed, respectively [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/22\" class=\"abstract_t\">22</a>]. After adjustment for age, sex, race, treating clinician, and duration of treatment, the difference in the proportion of patients who relapsed remained wide, but was no longer statistically significant (26.6 percent [95% CI 24.1-65.7 percent] and 43.8 percent [95% CI 16.3-40.3 percent], respectively). </p><p>High-dose <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> appeared to be well-tolerated; retinoid dermatitis was the only side effect that occurred significantly more often in the &ge;220 <span class=\"nowrap\">mg/kg</span> isotretinoin group (53.8 versus 31.6 percent). Additional studies are needed to confirm the results of this study as well as the safety of high-dose isotretinoin therapy.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">ISOTRETINOIN SAFETY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> is associated with a number of adverse effects that can be severe and limit its use. A 2018 systematic review of 11 randomized trials (760 patients) found that the overall frequency of adverse events was twice as high in the isotretinoin group as in the control group (99 versus 51 percent) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/28\" class=\"abstract_t\">28</a>]. Mucocutaneous side effects represented nearly 65 percent of all reported side effects, with cheilitis and xerosis being the most frequent. Severe adverse effects requiring withdrawal from the trial occurred in 12 patients taking isotretinoin (3.2 percent) and included elevated liver enzymes, cheilitis, xerosis, acne flare, photophobia, and Stevens-Johnson syndrome. (See <a href=\"#H9\" class=\"local\">'Mucocutaneous side effects'</a> below.) </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Teratogenicity and the iPLEDGE program</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> is teratogenic; it causes both spontaneous abortions and severe life-threatening congenital malformations [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/29\" class=\"abstract_t\">29</a>]. Embryopathy associated with exposure in the first trimester of pregnancy includes craniofacial, cardiac, thymic, and central nervous system malformations [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/30\" class=\"abstract_t\">30</a>]. Fetal abnormalities have not been attributed to the use of isotretinoin in men [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Among pregnant women exposed to <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, the risk of spontaneous abortion is approximately 20 percent; among pregnancies that progress, approximately 20 to 30 percent of neonates have evidence of embryopathy [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/31\" class=\"abstract_t\">31</a>]. Although data are limited, children who appear physically normal may have a higher rate of mental retardation and impaired neuropsychologic function.</p><p>Despite stringent rules in the United States intended to prevent women who are pregnant from beginning <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, and to prevent pregnancy while taking the drug [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/32\" class=\"abstract_t\">32</a>], some women taking isotretinoin still become pregnant. In 2006, the US FDA established a computer-based Risk Evaluation and Mitigation Strategy (REMS) risk management program with the goal of eliminating fetal exposure to isotretinoin (iPLEDGE). Prescribers, pharmacies dispensing isotretinoin, wholesalers distributing isotretinoin, and all patients receiving isotretinoin are required to comply with the registry requirements.</p><p>Access to the iPLEDGE program is available online (<a href=\"http://www.ipledgeprogram.com/&amp;token=P8TWCZAjeR8PUAmmngoTNM42X/3zlLk7kCgUxF48u8lvPdS4hlqHClPodeqVKM3g&amp;TOPIC_ID=38\" target=\"_blank\" class=\"external\">www.ipledgeprogram.com</a>). The iPLEDGE program requires the following [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All female patients of childbearing potential must select and commit to the use of two forms of birth control for at least one month prior to starting <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy, during therapy, and for one month after therapy. The forms of contraception that meet these requirements are specified by the iPLEDGE program.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All female patients who can become pregnant must have two negative urine or blood pregnancy tests (with a sensitivity of at least 25 <span class=\"nowrap\">mIU/mL)</span> before receiving the initial prescription. The second pregnancy test must be conducted in a CLIA-certified laboratory. For each month of therapy and one month after completing therapy, female patients must return to their clinicians for evaluation, counseling, education, and a pregnancy test conducted by a CLIA-certified laboratory.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For female patients who can become pregnant, prescribing clinicians must, on a monthly basis, document in the iPLEDGE system the results of the pregnancy test as well as report the two forms of birth control being used by the patient. The clinician must also confirm that the patient has received counseling and education. For all other patients, prescribers must document that the patient was counseled on the iPLEDGE program requirements, which include knowledge of the birth defects that may result from the use of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> by females of child-bearing potential.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As part of this system, clinicians must certify expertise in the diagnosis and treatment of acne, and knowledge of the risk and severity of birth defects with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>.</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Mucocutaneous side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mucocutaneous side effects of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, including cheilitis, dry skin and mucous membranes, epistaxis, desquamation, photosensitivity, and pruritus, are predictable and dose-dependent. The cheilitis can be significant and often requires the liberal use of topical emollients. Patients also have an increased risk of ocular symptoms related to dysfunction of meibomian glands within the conjunctiva [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/34,35\" class=\"abstract_t\">34,35</a>] and cutaneous staphylococcal infections [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/36\" class=\"abstract_t\">36</a>]. Paronychia, pyogenic granulomas, temporary diffuse alopecia, or nail brittleness may occasionally appear [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/37\" class=\"abstract_t\">37</a>]. </p><p>Skin fragility and cutaneous atrophy can occur during therapy, and dermabrasion and waxing should be avoided during treatment [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>]. Avoidance of chemical peels and laser treatments has also been proposed.</p><p class=\"headingAnchor\" id=\"H26534738\"><span class=\"h2\">Inflammatory bowel disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Observational studies have found conflicting results on the relationship between <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy and inflammatory bowel disease (IBD). A 2012 meta-analysis of three case-control studies and two additional unpublished studies did <strong>not</strong> find a statistically significant relationship between isotretinoin therapy and IBD (relative risk for IBD 0.94, 95% CI 0.65-1.36) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/38\" class=\"abstract_t\">38</a>]. The individual results of the three published case-control studies and a subsequent population-based cohort study are briefly summarized below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nested case-control study of 2008 patients with IBD and 19,814 matched controls found similar rates of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> use among the IBD and control groups. In the study, 1.2 percent of patients in the IBD group received isotretinoin prior to a diagnosis of IBD, and 1.1 percent of patients in the control group received isotretinoin prior to the date of IBD diagnosis for the corresponding index patients with IBD (odds ratio [OR] 1.16, 95% CI 0.73-1.77) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/39\" class=\"abstract_t\">39</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nested case-control study of 2159 women with IBD and oral contraceptive use and 43,180 matched female controls found that <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> treatment did not appear to increase the risk for IBD [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/38\" class=\"abstract_t\">38</a>]. The study adjusted for potential confounders, including a diagnosis of acne and the use of oral tetracyclines (adjusted risk ratio for IBD 0.99, 95% CI 0.52-1.90). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A nested case-control study of 8189 subjects with IBD and 21,832 matched controls found an increase in risk for ulcerative colitis among patients who had received <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (OR 4.36, 95% CI 1.97-9.66) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/40\" class=\"abstract_t\">40</a>]. The absolute risk for the disease was small, estimated at 14 excess cases within a population of 4428 patients with ulcerative colitis. A statistically significant relationship between Crohn's disease and isotretinoin treatment was not detected (OR 0.68, 95% CI 0.28-1.68).</p><p/><p>A 12-year cohort study of 46,922 patients treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, 184,824 patients treated with topical acne medication, and 1,526,946 untreated controls (all between the ages of 12 and 29) did not find a significant association between isotretinoin use and IBD on primary analysis (rate ratio 1.14, 95% CI 0.92-1.41) [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/41\" class=\"abstract_t\">41</a>]. Although an association between isotretinoin and IBD was detected in a subgroup of patients aged 12 to 19 years (rate ratio 1.39, 95% CI 1.03-1.87), a similar association was detected between the use of topical acne medications and ulcerative colitis (rate ratio 1.19, 95% CI 1.00-1.42), suggesting that acne may contribute to risk for IBD. More studies are necessary to determine whether isotretinoin therapy is a risk factor for IBD. Until additional information is available, during discussions of the potential adverse effects of isotretinoin with patients, it is reasonable to mention that although an increased risk for IBD has been reported, a relationship between these disorders remains to be proven.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Other side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> has been associated with a number of other side effects [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myalgias may occur in patients taking oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, particularly those who engage in vigorous physical activity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased night vision, corneal opacities, hepatotoxicity, and bone marrow suppression may occur infrequently.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertriglyceridemia occurs in up to 45 percent of patients on <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy and elevations of total cholesterol and low-density lipoprotein are seen in approximately 30 percent [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/42\" class=\"abstract_t\">42</a>]. These elevations are transient in about 80 percent of subjects and are rarely severe enough to require termination of therapy. (See <a href=\"#H12\" class=\"local\">'Monitoring and discontinuation'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> may cause idiopathic intracranial hypertension (pseudotumor cerebri). The use of medications that share this side effect (eg, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> antibiotics) should be avoided during therapy. (See <a href=\"topic.htm?path=idiopathic-intracranial-hypertension-pseudotumor-cerebri-epidemiology-and-pathogenesis#H5\" class=\"medical medical_review\">&quot;Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis&quot;, section on 'Medications'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse skeletal hyperostosis and calcifications in ligaments and tendons may rarely occur, especially among patients being treated with high doses for longer than usual periods.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Premature epiphyseal closure is a rare complication of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy. Only a few cases have been reported [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/43-47\" class=\"abstract_t\">43-47</a>], including some patients who received long-term or high-dose isotretinoin therapy [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/46,47\" class=\"abstract_t\">46,47</a>]. Two case reports describe premature epiphyseal closure in association with use of appropriate doses of isotretinoin for acne vulgaris in 14- and 16-year-old children [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Both patients presented with exercise-induced joint pain. Because of the rarity of this complication, routine radiologic screening for this occurrence in the absence of symptoms is not necessary. </p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Psychiatric effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Concerns have been raised about a possible association of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> with depression and suicide. Isotretinoin has been in the top 10 drugs reported to the FDA's Adverse Event Reporting System for depression and suicide attempts [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/48\" class=\"abstract_t\">48</a>]. Between the time isotretinoin was marketed in 1982 and January 2005, the FDA received reports of 190 patients in the United States treated with isotretinoin who committed suicide [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/49\" class=\"abstract_t\">49</a>].</p><p>If there were no association between <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> and suicide, 220 suicides would have been expected in users of isotretinoin in the US between 1982 and 2002, while there were actually only 165 suicides reported to the FDA in that time frame [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/49\" class=\"abstract_t\">49</a>]. However, not all such suicides would have been reported to the FDA so the interpretation of these numbers is uncertain.</p><p>Reviews, including a systematic review and meta-analysis, have concluded that data on suicidal behavior and depression during treatment with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> are inadequate to establish a causal relationship [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/50-54\" class=\"abstract_t\">50-54</a>]. Some authors have proposed that psychologic distress over severe acne, rather than isotretinoin, could be a contributing factor to suicide or depression in patients treated with the drug. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 3775 patients (ages 18 to 19 years), suicidal ideation was significantly more common among patients with severe acne, compared with patients with little or no acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/55\" class=\"abstract_t\">55</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A population-based cohort study using data from a large United Kingdom primary care database found that the risk of major depressive disorder was higher among patients with acne than in the general population without acne [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/56\" class=\"abstract_t\">56</a>]. This risk was highest within the first year of acne diagnosis (hazard ratio [HR] 1.63, 95% CI 1.33-2.00), after adjusting for age, sex, socioeconomic deprivation, comorbidities, smoking, alcohol use, and obesity, and decreased thereafter. The risk was unchanged after excluding patients who received <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition, a retrospective cohort study (n = 5756) that found an increased rate of suicide attempts in patients treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> compared with the general population also identified a nonsignificant trend towards elevated rates of suicide attempts prior to treatment with isotretinoin [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/57\" class=\"abstract_t\">57</a>]. </p><p/><p>In sum, the relationship between <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> and depression and suicide is uncertain. Patients should be advised of a possible link and should be followed closely for the development of depression or suicidal ideation [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-adults\" class=\"medical medical_review\">&quot;Suicidal ideation and behavior in adults&quot;</a> and <a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-children-and-adolescents-evaluation-and-management\" class=\"medical medical_review\">&quot;Suicidal ideation and behavior in children and adolescents: Evaluation and management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Monitoring and discontinuation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver function tests and fasting serum triglycerides and cholesterol should be obtained prior to initiating therapy [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2,12,25\" class=\"abstract_t\">2,12,25</a>]. Product information for <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> recommends checking fasting lipids weekly or biweekly until the lipid response has been established; however, in otherwise healthy, asymptomatic, young individuals without a personal or family history of diabetes or dyslipidemia, many practitioners perform laboratory testing on a less frequent basis. The findings of a systematic review and meta-analysis of studies reporting laboratory values during isotretinoin therapy for acne support less frequent testing; although isotretinoin was associated with statistically significant changes in the mean values of some laboratory tests (white blood cell count, hepatic panel, lipid panel), the changes did not meet criteria for high risk and the proportion of patients with laboratory abnormalities was low [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/58\" class=\"abstract_t\">58</a>]. In patients receiving isotretinoin for acne, we obtain a fasting lipid profile and liver function tests at baseline and repeat them after four and eight weeks of therapy. If these test results are normal and the dose of isotretinoin remains stable, we discontinue laboratory monitoring. </p><p>Women of childbearing potential must have a monthly serum or urine pregnancy test throughout the duration of therapy. A pregnancy test also should be performed one month after the last dose of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>.</p><p>Most of the adverse effects associated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> can be managed without discontinuing the drug (eg, emollients for dry skin, nonsteroidal antiinflammatory drugs for myalgias or arthralgias, dietary manipulation for lipid abnormalities).</p><p>Creatine kinase (CK) levels are elevated in approximately 15 to 50 percent of patients with isotretinoin-induced myalgias; however, checking CK levels is not indicated in the absence of severe muscular pain [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>]. Mild, transient elevations in hepatic transaminases occur early in the course of therapy in approximately 15 to 20 percent of patients; levels typically normalize within a few weeks [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Indications for stopping therapy include severe hypertriglyceridemia (eg, above 800 <span class=\"nowrap\">mg/dL</span> or 9 <span class=\"nowrap\">mmol/L)</span> because of the risk of acute pancreatitis [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/59\" class=\"abstract_t\">59</a>], and other marked abnormalities on laboratory testing. Discontinuation of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is recommended if hepatic transaminase levels reach more than three times greater than normal values [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2,25\" class=\"abstract_t\">2,25</a>].</p><p>Although hypertriglyceridemia usually resolves with cessation of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, patients may need ongoing monitoring since one report suggests that they may be at increased risk for future hyperlipidemia and the metabolic syndrome [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/60\" class=\"abstract_t\">60</a>]. In a cross-sectional study, 102 patients in whom the serum triglyceride concentration increased at least 89 <span class=\"nowrap\">mg/dL</span> (1.0 <span class=\"nowrap\">mmol/L)</span> during isotretinoin therapy (hyper-responders) were compared with 100 patients in whom the serum triglyceride concentration changed &le;9 <span class=\"nowrap\">mg/dL</span> (0.1 <span class=\"nowrap\">mmol/L,</span> nonresponders). Four years after completion of isotretinoin therapy, hyper-responders were significantly more likely to have hypertriglyceridemia (odds ratio [OR] 4.8, 95% CI 1.6-13.8), hypercholesterolemia (OR 9.1, 95% CI 1.9-43), truncal obesity (OR 11.0, 95% CI 2.0-59), and hyperinsulinemia (OR 3.0, 95% CI 1.6-5.7).</p><p class=\"headingAnchor\" id=\"H424162929\"><span class=\"h2\">Cutaneous procedures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Delaying cutaneous procedures until at least 6 to 12 months after the completion of oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy is commonly practiced due to concern for increased risk for abnormal scarring and delayed wound healing; however, data to support this action are limited. Based upon a systematic review of the literature, a multispecialty panel of experts found insufficient evidence to recommend delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures [<a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/61\" class=\"abstract_t\">61</a>]. The panel recommended avoidance of mechanical dermabrasion and fully ablative laser procedures in patients with recent isotretinoin use based upon limited evidence suggesting increased risk for scarring. Although prospective controlled trials are necessary to confirm the level of risk associated with cutaneous procedures in this population, the findings of the systematic review aid in counseling patients who may benefit from earlier performance of procedures.</p><p class=\"headingAnchor\" id=\"H4065352350\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acne-vulgaris\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acne vulgaris&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=acne-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Acne (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=acne-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Acne (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> is an effective treatment for acne vulgaris that diminishes sebum production, inhibits the growth of <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em>, and inhibits comedogenesis. However, multiple adverse effects limit its widespread use. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> is teratogenic. Women of childbearing potential must use two forms of contraception during treatment and for one month thereafter. For patients with severe, recalcitrant, nodular acne who have not responded to other topical and oral therapies, we recommend use of oral isotretinoin (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). For patients with less severe but treatment-resistant acne that is scarring or psychologically disabling, we also suggest use of oral isotretinoin (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>). Isotretinoin should NOT be administered in pregnancy. (See <a href=\"#H3\" class=\"local\">'Clinical use'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In order to diminish treatment-induced flares, <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> is typically started at a low dose (0.5 <span class=\"nowrap\">mg/kg/day)</span> during the first month of therapy, and then increased to 1 <span class=\"nowrap\">mg/kg/day</span>. A total treatment dose of 120 to 150 <span class=\"nowrap\">mg/kg</span> of isotretinoin given over four to six months may decrease the risk of relapse compared with lower total doses. (See <a href=\"#H3\" class=\"local\">'Clinical use'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) may require concomitant treatment with systemic glucocorticoids starting before or at the initiation of oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy. (See <a href=\"#H3\" class=\"local\">'Clinical use'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other systemic acne medications are typically discontinued during <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy. In particular, the use of isotretinoin with tetracycline-class antibiotics should be avoided due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri). (See <a href=\"#H3\" class=\"local\">'Clinical use'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients improve after <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy, although the majority of patients will continue to require the use of other acne therapies. Subsequent courses of isotretinoin should not be initiated until at least five months after completion of the previous treatment period. A second course of isotretinoin is needed in approximately 20 percent of patients. (See <a href=\"#H6\" class=\"local\">'Response to therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the United States, all prescribing clinicians and patients are required to participate in the iPLEDGE program, an online registry initiated by the FDA to minimize the risk of fetal exposure to <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>. (See <a href=\"#H8\" class=\"local\">'Teratogenicity and the iPLEDGE program'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> has multiple side effects, including teratogenicity, mucocutaneous disorders, myalgias, visual changes, idiopathic intracranial hypertension, hepatotoxicity, and hyperlipidemia. Patients should be screened for these and other complaints via questioning and laboratory studies at regular follow-up visits during treatment. In women of childbearing potential, a monthly serum or urine HCG is required during the duration of therapy. HCG should be repeated one month following therapy. (See <a href=\"#H7\" class=\"local\">'Isotretinoin safety'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An association of <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> with depression and suicide has been proposed. Although studies have concluded that a causal relationship cannot be definitively established, patients should be advised of these risks, and should be asked to report any symptoms of depression. (See <a href=\"#H11\" class=\"local\">'Psychiatric effects'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/1\" class=\"nounderline abstract_t\">Ward A, Brogden RN, Heel RC, et al. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28:6.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/2\" class=\"nounderline abstract_t\">Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/3\" class=\"nounderline abstract_t\">Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/4\" class=\"nounderline abstract_t\">Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet 1980; 2:1048.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/5\" class=\"nounderline abstract_t\">Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980; 3:602.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/6\" class=\"nounderline abstract_t\">Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6:735.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/7\" class=\"nounderline abstract_t\">Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186:123.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/8\" class=\"nounderline abstract_t\">McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127:341.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/9\" class=\"nounderline abstract_t\">Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108:333.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/10\" class=\"nounderline abstract_t\">Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10:490.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/11\" class=\"nounderline abstract_t\">Nagler AR, Milam EC, Orlow SJ. The use of oral antibiotics before isotretinoin therapy in patients with acne. J Am Acad Dermatol 2016; 74:273.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/12\" class=\"nounderline abstract_t\">Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/13\" class=\"nounderline abstract_t\">Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999; 141:307.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/14\" class=\"nounderline abstract_t\">Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28:572.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/15\" class=\"nounderline abstract_t\">B&ouml;ni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 2003; 4:273.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/16\" class=\"nounderline abstract_t\">Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 1986; 278:307.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/17\" class=\"nounderline abstract_t\">Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:644.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/18\" class=\"nounderline abstract_t\">Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 2013; 69:762.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/19\" class=\"nounderline abstract_t\">L&oacute;pez-V&iacute;lchez MA, Vicente Villa MA, Garc&iacute;a-Fructuoso MT, et al. [Acne fulminans after the treatment with isotretinoin]. An Esp Pediatr 1999; 51:200.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/20\" class=\"nounderline abstract_t\">Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/21\" class=\"nounderline abstract_t\">Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/22\" class=\"nounderline abstract_t\">Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149:1392.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/23\" class=\"nounderline abstract_t\">Azoulay L, Oraichi D, B&eacute;rard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/24\" class=\"nounderline abstract_t\">White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998; 134:376.</a></li><li class=\"breakAll\">Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, Philadelphia 2007. p.275.</li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/26\" class=\"nounderline abstract_t\">Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/27\" class=\"nounderline abstract_t\">Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/28\" class=\"nounderline abstract_t\">Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 2018; 178:76.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/29\" class=\"nounderline abstract_t\">Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/30\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Accutane-exposed pregnancies--California, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:28.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/31\" class=\"nounderline abstract_t\">Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/32\" class=\"nounderline abstract_t\">Vastag B. More stringent rules on accutane. JAMA 2002; 287:832.</a></li><li class=\"breakAll\">www.ipledgeprogram.com (Accessed on April 23, 2009).</li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/34\" class=\"nounderline abstract_t\">Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol 2012; 148:803.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/35\" class=\"nounderline abstract_t\">Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/36\" class=\"nounderline abstract_t\">Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987; 123:606.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/37\" class=\"nounderline abstract_t\">Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/38\" class=\"nounderline abstract_t\">Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol 2013; 149:216.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/39\" class=\"nounderline abstract_t\">Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009; 104:2774.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/40\" class=\"nounderline abstract_t\">Crockett SD, Porter CQ, Martin CF, et al. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105:1986.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/41\" class=\"nounderline abstract_t\">Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133:907.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/42\" class=\"nounderline abstract_t\">Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/43\" class=\"nounderline abstract_t\">Steele RG, Lugg P, Richardson M. Premature epiphyseal closure secondary to single-course vitamin A therapy. Aust N Z J Surg 1999; 69:825.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/44\" class=\"nounderline abstract_t\">Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. Joint Bone Spine 2012; 79:314.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/45\" class=\"nounderline abstract_t\">Inamo Y, Suzuki T, Mugishima H. A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblasoma. Endocr J 1999; 46 Suppl:S113.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/46\" class=\"nounderline abstract_t\">Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 1982; 7:663.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/47\" class=\"nounderline abstract_t\">Lawson JP, McGuire J. The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Skeletal Radiol 1987; 16:91.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/48\" class=\"nounderline abstract_t\">Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45:515.</a></li><li class=\"breakAll\">www.fda.gov/cder/drug/InfoSheets/HCP/IsotretinoinHCP.htm (Accessed on August 12, 2005).</li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/50\" class=\"nounderline abstract_t\">Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005; 24:92.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/51\" class=\"nounderline abstract_t\">Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55:134.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/52\" class=\"nounderline abstract_t\">Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23:665.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/53\" class=\"nounderline abstract_t\">Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol 2008; 144:1197.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/54\" class=\"nounderline abstract_t\">Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 76:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/55\" class=\"nounderline abstract_t\">Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011; 131:363.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/56\" class=\"nounderline abstract_t\">Vallerand IA, Lewinson RT, Parsons LM, et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol 2018.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/57\" class=\"nounderline abstract_t\">Sundstr&ouml;m A, Alfredsson L, Sj&ouml;lin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341:c5812.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/58\" class=\"nounderline abstract_t\">Lee YH, Scharnitz TP, Muscat J, et al. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. JAMA Dermatol 2016; 152:35.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/59\" class=\"nounderline abstract_t\">McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/60\" class=\"nounderline abstract_t\">Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136:582.</a></li><li><a href=\"https://www.uptodate.com/contents/oral-isotretinoin-therapy-for-acne-vulgaris/abstract/61\" class=\"nounderline abstract_t\">Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol 2017; 153:802.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 38 Version 28.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL USE</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Indications</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Administration</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">RESPONSE TO THERAPY</a><ul><li><a href=\"#H29706373\" id=\"outline-link-H29706373\">Low dose isotretinoin</a></li><li><a href=\"#H82308305\" id=\"outline-link-H82308305\">High-dose isotretinoin</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">ISOTRETINOIN SAFETY</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Teratogenicity and the iPLEDGE program</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Mucocutaneous side effects</a></li><li><a href=\"#H26534738\" id=\"outline-link-H26534738\">Inflammatory bowel disease</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Other side effects</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Psychiatric effects</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Monitoring and discontinuation</a></li><li><a href=\"#H424162929\" id=\"outline-link-H424162929\">Cutaneous procedures</a></li></ul></li><li><a href=\"#H4065352350\" id=\"outline-link-H4065352350\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H13\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=hormonal-therapy-for-women-with-acne-vulgaris\" class=\"medical medical_review\">Hormonal therapy for women with acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=idiopathic-intracranial-hypertension-pseudotumor-cerebri-epidemiology-and-pathogenesis\" class=\"medical medical_review\">Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acne-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Acne (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acne-the-basics\" class=\"medical medical_basics\">Patient education: Acne (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acne-vulgaris\" class=\"medical medical_society_guidelines\">Society guideline links: Acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-adults\" class=\"medical medical_review\">Suicidal ideation and behavior in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-children-and-adolescents-evaluation-and-management\" class=\"medical medical_review\">Suicidal ideation and behavior in children and adolescents: Evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acne-vulgaris\" class=\"medical medical_review\">Treatment of acne vulgaris</a></li></ul></div></div>","javascript":null}